Can-Fite BioPharma Ltd. (CANF) 株式分析

企業概要

Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical enterprise dedicated to the development of orally bioavailable small molecule therapeutic products designed to address cancer, liver inflammatory diseases, and erectile dysfunction within the Israeli market. The company functions within the healthcare sector, specifically the biotechnology industry, a domain characterized by high research and development expenditures and significant regulatory scrutiny before products reach commercialization. With a market capitalization of 6.88 百万米ドル and annual revenue of 405,000 米ドル across five employees, the firm represents a micro-cap entity with minimal operational footprint. These valuation and revenue figures indicate that the company is in an early-stage development phase where financial resources are primarily allocated toward advancing clinical candidates rather than generating substantial commercial cash flows or establishing a large-scale manufacturing base.

財務健全性

The company reported total revenue of 405,000 米ドル for the trailing twelve months, while net income stood at a loss of 9,828,000 米ドル and EBITDA reached a negative 9,926,000 米ドル. The substantial discrepancy between the modest revenue figure and the significant net loss highlights a cost structure dominated by high fixed costs associated with clinical trial operations and R&D expenses that far exceed current sales. Free cash flow was negative at 4,985,750 米ドル, which signifies that the company is burning through its cash reserves to fund its development pipeline and lacks the operational liquidity to self-finance its activities without external financing. Gross margin stands at 100.0%, reflecting a lack of cost of goods sold relative to sales in this pre-commercial stage, whereas the operating margin of -2,488.7% and profit margin of 0.0% demonstrate severe operational inefficiencies relative to current revenue generation capabilities. The balance sheet holds 8.54 百万米ドル in cash against 71,000 米ドル of debt, resulting in a debt-to-equity ratio of 1.27, which suggests the company is leveraged relative to its equity base despite holding a cash cushion. The current ratio of 3.46 indicates strong short-term liquidity relative to immediate obligations, providing a buffer against near-term payment requirements. However, the return on equity of -178.2% and return on assets of -66.7% reveal that management is currently destroying shareholder and asset value, a typical characteristic of clinical-stage firms but one that signals significant financial risk until profitability is achieved.

バリュエーション評価

The trailing twelve-month P/E ratio is not available due to negative earnings, while the forward P/E is reported at -4.01, a metric that implies earnings are expected to remain negative in the near term or that valuation models are relying on non-GAAP adjustments or future projections that have not yet materialized. The price-to-book ratio of 0.69 suggests the market is valuing the company at a discount relative to its book value, potentially reflecting skepticism about the commercial viability of its lead drug candidate, Piclidenoson. The price-to-sales ratio of 16.98 and EV/EBITDA of -0.41 serve as alternative valuation metrics that indicate the market is pricing the asset based on its intellectual property potential rather than current profitability. The 52-week trading range spans from a low of 2.93 米ドル to a high of 36.40 米ドル, placing the current market price significantly below the recent 52-week high and well above the 52-week low. The beta of -0.10 indicates that the stock's price volatility moves inversely to the broader market, a rare characteristic for equity securities that suggests idiosyncratic factors dominate its price movement rather than general market sentiment.

Growth & Income

Revenue growth year-over-year declined by 43.3%, while earnings growth is not available due to the company's history of losses. Since the earnings growth rate is not calculable against a positive baseline, the decline in revenue directly contributes to the contraction in total earnings, implying that the company is struggling to maintain or expand its commercial footprint in a shrinking sales environment. As the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders, meaning all available capital must be reinvested into operations or raised from external sources to sustain development efforts. The overall growth and income profile is characterized by negative revenue momentum, a complete absence of dividend income, and a reliance on existing cash reserves to bridge the gap between current operations and the eventual commercialization of therapeutic products.